<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234127</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0244</org_study_id>
    <nct_id>NCT03234127</nct_id>
  </id_info>
  <brief_title>Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia</brief_title>
  <acronym>SAFIR</acronym>
  <official_title>Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of SAFIR is to identify the atherosclerotic genetic factors in these
      patients, which will identify new therapeutic targets for the treatment of CV and Familial
      Hypercholesterolemia diseases. In addition, SAFIR will allow the identification of new CV
      protection biomarkers, which will be useful tools for the development of a personalized
      medicine for the management of dyslipidemias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the SAFIR study is to perform non-invasive coronary vascular phenotyping of
      familial hypercholesterolemia (FH) families by performing a coronary calcium score and then
      to detect protective genetic factors in patients who do not have a significant atheroma
      despite a perturbed biological phenotype.

      The investigators will also conduct biochemical, lipidemic and metabolomic analyzes to
      identify a signature of biomarkers protective of cardiovascular risk in FH patients.

      The investigators will use the French FH register, which already includes 3889 patients, to
      identify these &quot;protected&quot; FH families within the main reference centers for the management
      of FH for inclusion and follow-up of patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genes associated with the resistance to development of coronary atherosclerosis in subjects with heterozygous familial hypercholesterolemia</measure>
    <time_frame>3 years</time_frame>
    <description>Identification of functional genetic variants by a Whole Genome Sequencing (WGS) approach in case-control analysis (FH without and with advanced coronary atherosclerosis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of new biochemical, lipidemic, metabolomic and metagenomic biomarkers associated with cardiovascular protection in FH patients.</measure>
    <time_frame>3 years</time_frame>
    <description>Lipidic panel, phosphocalcic panel, Ceramides, Alipoproteins, Lp(a), lipidomic, LDL size, Phospholipids, TMAO, Carnitin, Cholin, microbiota, metabolomic, LDL Ox, Sterols, Isoprostan, oxidation, inflammation, cytokins, oxidative stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of arterial stiffness (reflected by the pulse wave velocity) with the development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of arterial stiffness measured by popmeter® (pulse wave velocity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of atherosclerosis of supra-aortic trunks (AST) with the development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of ASD through arterial Doppler ultrasonography (Intra-media thickness (IMT), degree of stenosis (ESCT), plaque)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of atherosclerosis of the lower limbs with the development of coronary atherosclerosis (PAD) in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of lower extremity involvement by arterial doppler ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between aortic valvular score and development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between coronary calcium score and aortic valvular score in HF patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Atherosclerosis- resistance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FH Patient without atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FH patient with atheroclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole Genome Sequencing</intervention_name>
    <description>Whole Genome Sequencing Biomarkers analyses</description>
    <arm_group_label>Atherosclerosis- resistance</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Biological analyzes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient agreeing to sign the consent of the study and the consent of biocollection

          -  Patient suffering from a familial hypercholesterolemia with a clinically-biologic
             score DLCN (Dutch Lipid Clinic Network, Annex 2)&gt; 8 and / or a causative mutation
             identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.

          -  Patient with a coronary calcium score

          -  Men ≥ 45 years of age; Female ≥ 55 years

          -  Patient affiliated to an existing social insurance

        The inclusion criteria to be met in the population with known coronary atheroma:

          -  Subjects for secondary prevention of a coronary event or ischemic heart disease,
             irrespective of the result of the coronary calcium score

          -  Primary prevention topic CV with calcium score ≥ 400 Agatston units

        Inclusion criteria to be met in the population without cardiovascular risk:

        - No cardiovascular event (including MI, coronary revascularization, angina, stroke,
        Transiant ischemic attack, PAD) with: For women between 55 and 65 years, a calcium score *
        For women over 65 years old, a calcium score * ≤ 10 Agatston units For men between 45 and
        55 years old, a calcium score * For men over 55 years old, a calcium score * ≤ 10 Agatston
        units

        * Less than 5 years

        Exclusion Criteria:

          -  Subject suffering from cancer or progressive neoplasia

          -  Subjects who underwent radiotherapy covering the cardiac field

          -  Subject treated with recent corticosteroid therapy

          -  Subjects with unsubstituted or poorly controlled hypothyroidism (TSH&gt; normal)

          -  Subject of the Human Immunodeficiency Virus (HIV)

          -  Subject receiving immunosuppressive or anti-cancer treatment

          -  Subject refusing to participate

          -  Subjects under tutelage, curatorship or a safeguard of justice or without social
             insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthieu PICHELIN</last_name>
    <phone>02 53 48 27 06</phone>
    <email>matthieu.pichelin@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bertrand CARIOU, Pr</last_name>
    <phone>02.53.48.27.07</phone>
    <email>bertrand.cariou@univ-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Le Bocage Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>29079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves COTTIN, Pr</last_name>
      <phone>03.80.28.12.55</phone>
      <email>yves.cottin@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Yves COTTIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louis Pradel Cardiovascular Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe MOULIN, Pr</last_name>
      <phone>04.72.68.13.04</phone>
      <email>philippe.moulin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe MOULIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Conception Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie BELIARD, Dr</last_name>
      <phone>04.91.38.36.50</phone>
      <email>Sophie.BELIARD@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie BELIARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand CARIOU, Pr</last_name>
      <phone>02.53.48.27.07</phone>
      <email>bertrand.cariou@univ-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand CARIOU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck BOCCARA, Dr</last_name>
      <phone>01.49.28.24.49</phone>
      <email>franck.boccara@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Franck BOCCARA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric BRUCKERT, Pr</last_name>
      <phone>01.42.17.57.85</phone>
      <email>eric.bruckert@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Eric BRUCKERT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François PAILLARD, Dr</last_name>
      <phone>02.99.28.25.40</phone>
      <email>francois.paillard@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>François PAILLARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean FERRIERES, Pr</last_name>
      <phone>05.61.32.33.39</phone>
      <email>ferrieres.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean FERRIERES, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

